{'fraction_non_alphanumeric': 0.05526315789473684, 'fraction_numerical': 0.02894736842105263, 'mean_word_length': 5.201086956521739, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Facial Pain With Recurrent Facial Palsy

P .05). Curiously, in this article no formal statistical comparison is made between frovatriptan (AEs affecting 47% of patients in all trials) and placebo (AEs affecting 34%). Even so, in this “comprehensive tolerability and safety assessment of frovatriptan,” the authors’ conclusion is that the drug has “an adverse events profile similar to that of placebo and superior to that of sumatriptan 100 mg.” 3 To our analysis, however, the Fisher exact test shows that frovatriptan caused significantly more AEs than placebo (difference, 13%; 95% confidence interval (CI), 9% to 17%; P .00005). Of central and peripheral nervous system AEs (including dizziness, paresthesiae, and headache), more were recorded with frovatriptan (18%) than with placebo (12%; difference, 6%; 95% CI, 3% to 9%; P .01). In conclusion, we are concerned that some of the published conclusion derived from frovatriptan’s clinical development trials program may be incompletely founded and misleading. If true, this is unfortunate, as this sponsored supplement is currently the only source of published data from these trials.